Therapeutic Effects of Oral Desmopressin for Men with Nocturia and Benign Prostatic Hyperplasia (BPH): a Preliminary Clinical Trial

Document Type : Research Paper

Authors

1 Professor of urology, Emam Reza Hospital, Mashad, Iran

2 Assistant professor of urology, Emam Reza Hospital, Mashad, Iran

Abstract

Introduction
Nocturia commonly seen with aging may result from several conditions of which benign prostatic hyperplasia (BPH) and loss of nighttime vasopressin production (or release) are very common causes. The relief of obstructive symptoms of BPH without addressing the nocturnal polyuria may result in disappointing clinical results.
.Materials and Methods
A total of adult men (mean age: 62+ /- 2.5 years old) with BPH and bothering nocturia (> or = 2voids / night) were treated with oral desmopressin at bedtime. Exclusion criteria included active urinay tract infection, history of myocardial infarction, congestive heart failure, angina and hyponatremia. Patients received desmopressin tablets (0.1,0.2,or 0.4mg ) during a 3 – wk dose titration period and after 1- wk washout period the effective drug dose continued for 6 to 8 – wk . Positive Clinical response defined as > or =50% decrease in nocturnal voiding episodes.
Results
All intervened patients improved with such a treatment. The average of symptoms duration was 3.45 +/- 0.62 years. Nocturia episodes decreased from a mean of 4 +/- 0.36 episodes/ night before treatment to1.17 +/- 0.28 episodes/ night after therapy (p< 0.0001). I-PSS decreased from 16.9 +/- 1.16 before treatment to10.47 +/- 0.98 after therapy (p< 0.0001). Serum sodium levels changes were significant (p= 0.02), but hyponatremia did not occur. Also, there was a correlation between age and nocturia episodes (p< 0.0001, r = 0.744.
Conclusion
Oral desmopressin tablets provide an effective and well tolerated treatment for nocturia due to BPH and cause significant reduction in nocturia episodes; I-PSS measures serum sodium levels with limited side effects.

Keywords

References

1- Abrams P, Drake M. Overactive bladder, Campbell’s Urology. Wein:Kavoussi, Pertin Peters; 2007.p. 2079 – 2091.
2- Neil M. Resnick, Subbarao V. Ylla. Geriatric incontinence and voiding dysfunction. Campbell’s Urology .Wein:
Kavoussi, Pertin, Peters; 2007.p. 2305 – 2321.
3- Granados Loarca EA, Garat Barredo JM, Villavicencio Marrich H.The use of desmopressin as an alternative in the
treatment of nocturia in patients with bennign prostatic hyperplasia (BPH). Actas Urol Esp 1999; 23:56-59.
4- Schneider T, de la Rosette JJ, Michel MC. Nocturia: a non – specific but important symptm of urological diseases.
Int J Urol 2009; 16:249-256.
5- Andersson KE, Alany. Wein .Phamacologic management of storage and emptying failure. Campbell’s Urology
Wein: Kavoussi, Pertin, Peters; 2007.p. 2091–2123.
6- Mansson W, Sundint Gullberg B. Evaluation of a synthetic vaspressin a ralogue for treatment of nocturia in benign
prostatic hypertrophy. Ad ouble blind study. Scand J Urol Nephrol 1980; 14:139 –141.
7- Hodr , Lin WY, WU CF , Shee JJ, Huang YC, Chen CS. linical observation of the effect of antidiuretic hormone on
nocturia in elderly man. BJU Int 2005; 96:1310 – 1313.
8- Jin MH, Moon du G.Practical management of nocturia in uroloy. Indian J Urol 24:289 – 94.
9- Chancellor MB, Atan A, Riras DA, Watanabet, Tai HL, Kumon H. Beneficial effect of intranasal desmopressin for
men with benign prostatic hyperplasia and nocturia : Perliminary results. Tech Urol 1999; 5: 191– 194.
10- Rembratt A, Norgaard JP, Andersson KE. Desmopressin elderly patients with nocturia: short – term safetly and
effects on urine out put , sleep and voiding patterns. BJU Int 2003; 91:642– 646.
11- Naghizadeh S, Kefi A, Dogan HS, Burgu B, Akdogan B, Tekgul S. Effectiveness of oral desmopressin therapy in
posterior urethral valve patients with polyuria and detection of factors effecting the therapy. Eur Urol 2005; 48:819 –
25 Pub 2005 Jan 22.
12- Terada N, Arakaki R, Okaday, Kitahara M, Kaneko Y, Omori K, Nishimura K. Efficacy of intranasal
desmopressin in the treatment of nocturia due to noctural polyuria. Hinyokika kiyo 2005; 51:151 –154.
13- Valiquqtlw G, Herbert J, Maede – D Alisera P. Desmopressin in the management of nocturia in patients with
multiple sclerosis. A double – Blind, Crossover trial. Arch Neurol 1996; 53:1270 –1275.
14- Kuo HC. Efficacy of desmopressin in treatment of refractory nocturia in patients older than 65 years. Urology
2002; 59:485 – 459.
15- Chancellor MB, Atan A, Rivas DA , Watarablet, Tai HL, Kumov H. Beneficial effect of intranasal desmopressin
for men with benign prostatic hyper plasia and nocturia : Preliminary results. Tech Urol 1999; 5:191–194.
16- Mansson W, Sundin T, Gullberg B. Evaluation of a synthetic vasperssin analogue for treatment of nocturia in
benign proatatic hypertrophy, A double blind study. Scandy J Urol Nephrol 1980; 14:139–141. 
Medical Journal of Mashhad university of Medical Sciences
Volume 53, Issue 2 - Serial Number 2
May and June 2009
Pages 63-68

Files

Share

How to cite

Statistics